Technology to identify genes

May 04, 2011
Technology to identify genes

(Medical Xpress) -- King’s researchers in the Division of Cancer Studies have developed new technology for the identification and validation of microRNA (miRNA) targets in research and clinical diagnostics, resulting in an exclusive licence agreement with Sigma Life Science announced today.

Patented by King’s Business, this technology is now being co-developed with Sigma Life Science into a kit ready for commercialization.

miRNAs function as critical regulators of gene expression in eukaryotic cells, with over 1,000 different miRNAs in the human genome already known to play multiple roles in gene regulation. Although the specific targets of most miRNAs are largely unknown, aberrant expression of miRNAs has been implicated in numerous disease states, making them important targets for clinical research in oncology, wound healing and infectious disease.

Currently, identification of miRNA targets is laborious and inefficient, relying on computer algorithms and subsequent validation by in vitro assays. To overcome this research bottleneck, scientists in the Division of Cancer Studies at King’s have developed a technology allowing simple, accurate identification and validation of miRNA targets.

Dr. Joop Gaken, lead King’s researcher of this project, explained: "The role of miRNAs in cancer is well established, and several miRNAs clearly function as either oncogenes or tumor suppressor , although the target genes are unknown in the majority of cases. This new test will enable the straightforward identification of target genes that are strongly regulated by a given miRNA, helping to elucidate important gene regulation events in vivo."

"miRNA research is a rapidly growing field, and this test will be an invaluable asset to commercial and academic researchers working with miRNAs," commented Steven Suchyta at Sigma Life Sciences. "The exclusive license agreement has allowed Sigma Life Science and King’s College London to work closely together to ensure rapid development of this technology for the benefit of the research community, and underlines our commitment to accelerating scientific discovery through innovative technology."

Dr. Mike Shaw, Director of Commercial Development in King’s Business commented: "We are delighted to see this innovative technology commercialized by a leading life science company. The licence agreement has enabled close working between King’s and Sigma Life Science to take the technology efficiently through further development steps. We are excited about the opportunity for our technology to appear as a product for the research community in the relatively near future."

Explore further: A nucleotide change could initiate fragile X syndrome

add to favorites email to friend print save as pdf

Related Stories

Useful biomarkers for esophageal squamous cell carcinoma

Jan 25, 2011

A research team from China investigated the expression profile of miRNA in esophageal squamous cell carcinoma (ESCC). They found that miRNAs were deregulated and miR-143 and miR-145 were downregulated in ESCC.

Researchers Identify microRNA targets in C. elegans

Jan 10, 2010

MicroRNAs (miRNAs) are non-coding RNAs that impact almost every aspect of biology. In recent years, they have been strongly implicated in stem cell biology, tissue and organism development, as well as human conditions ranging ...

Team find gene signature profile for metastasis

May 31, 2008

A common signature of tiny, specific pieces of non-coding genetic material known as microRNAs (miRNAs) may be directly involved in the spread of cancer to other parts of the body. Researchers at the Kimmel Cancer Center at ...

Researchers discover how microRNAs control protein synthesis

Jul 09, 2007

While most RNAs work to create, package, and transfer proteins as determined by the cell’s immediate needs, miniature pieces of RNA, called microRNAs (miRNAs) regulate gene expression. Recently, researchers from the University ...

Recommended for you

Throwing a loop to silence gene expression

13 hours ago

All human cells contain essentially the same DNA sequence – their genetic information. How is it possible that shapes and functions of cells in the different parts of the body are so different? While every cell's DNA contains ...

A nucleotide change could initiate fragile X syndrome

Sep 01, 2014

Researchers reveal how the alteration of a single nucleotide—the basic building block of DNA—could initiate fragile X syndrome, the most common inherited form of intellectual disability. The study appears ...

Gene clues to glaucoma risk

Aug 31, 2014

Scientists on Sunday said they had identified six genetic variants linked to glaucoma, a discovery that should help earlier diagnosis and better treatment for this often-debilitating eye disease.

User comments : 0